Merck invests in diabetes through KalVista deal

By taking a stake in KalVista, the big pharma aims to buffer its diabetes franchise with related therapies. 

By Lisa LaMotta • Oct. 11, 2017

Express Scripts drops $3.6B for healthcare management company

The PBM said this latest acquisition furthers its "goal of becoming the nation's leading patient benefit manager."

By Jacob Bell • Oct. 10, 2017

Pfizer mulls sale of consumer health business

A potential sale of the unit, which includes brands like Advil and Centrum, would allow Pfizer to focus resources on its higher-earning pharma division. 

By Lisa LaMotta • Oct. 10, 2017

AbbVie solidifies its I/O pipeline with Turnstone deal

A new agreement hands AbbVie the option to exclusively license up to three oncolytic viral immunotherapies.

By Jacob Bell • Oct. 10, 2017

Prescribed Reading: DMD, MS and other acronyms

Another DMD drug struggles to get closer to market, a blockbuster MS drug now faces multiple generic competitors, and a deal is inked to increase competition in the Tyk2 inhibitor space. 

By Lisa LaMotta • Oct. 6, 2017

Lonza snatches Shire facility as biologics manufacturing rakes in returns

The drug developer expects the new site will complement operations from another mammalian manufacturing plant in the U.K.

By Jacob Bell • Oct. 5, 2017

Amgen digs deeper in I/O with CytomX deal

More than a billion dollars in milestone payments is on the line as the drugmakers work on developing therapies using CytomX's Probody technology.

By Jacob Bell • Oct. 4, 2017

Celgene snaps up Nimbus assets in immunology deal

The deal gives the big biotech access to Nimbus' deep computational expertise and options to programs from the alliance.

By Suzanne Elvidge • Oct. 4, 2017

Endocyte shares shoot up on prostate cancer pact

The Indiana biopharma aims to pivot from R&D setbacks with a licensing deal for a new lead candidate.

By Suzanne Elvidge • Oct. 3, 2017

In RARE news, Dimension dumps Regenxbio for better offer

Ultragenyx's superior offer has trumped the previously announced deal for the gene therapy developer. 

By Suzanne Elvidge • Oct. 3, 2017

Prescribed Reading: No such thing as unicorns

Both closely watched Axovant and Intarcia had major setbacks this week, despite high hopes that their therapies would be game-changers. 

By Lisa LaMotta • Sept. 29, 2017

Arcturus to go public through merger with Alcobra

Combining with Alcobra will give currently private Arcturus access to public markets, while adding cash for development of its RNA-focused pipeline. 

By Suzanne Elvidge • Sept. 29, 2017

NewLink inks deal with AstraZeneca to test Imfinzi combo

IDO inhibitors like NewLink's indoximod are seen as a potentially fruitful pairing for PD-L1 inhibitors.   

By Suzanne Elvidge • Sept. 27, 2017

Prescribed Reading: Consolidation, clinical holds and landmark results

The FDA continues its clinical hold spree for PD-1/L1s, consolidation is rampant in the CDMO space and RNAi may become a reality very soon. 

By Lisa LaMotta • Sept. 22, 2017

Cellectar, Onconova partner on cancer drug conjugates

An early-stage collaboration could boost the two small-cap biotechs' pipelines.

By Suzanne Elvidge • Sept. 22, 2017

Taiho taps Arcus in latest I/O deal

The two biotechs have inked a development and commercialization agreement for immuno-oncology assets in Asia. 

By Suzanne Elvidge • Sept. 21, 2017

Swedish CDMO picks up facility, supply contract in deal with Roche

Roche has offloaded several small molecule-focused sites in a shift toward biologics production.

By Suzanne Elvidge • Sept. 21, 2017

Teva teams up with Nuvelution in Tourette

The companies are planning a late-stage program that will evaluate Austedo, which has already locked down two indications this year, as a treatment for children with the syndrome.

By Suzanne Elvidge • Sept. 20, 2017

Catalent adds biologics manufacturing with $950M Cook Pharmica deal

The contract developer is building out its capabilities to encompass development through commercialization.

By Lisa LaMotta • Sept. 19, 2017

Teva offloads the rest of its women's health business for $1.4B

The deals put Teva past its goal of selling $2 billion worth of assets by year's end.

By Jacob Bell • Sept. 19, 2017

Ultragenyx trying to snag Regenxbio's takeover target

Dimension Therapeutics now has another buyout offer to consider.

By Jacob Bell • Sept. 18, 2017

AstraZeneca's latest sale rakes in $555M

The British pharma has been monetizing older, non-core assets as it focuses on core therapeutic areas. 

By Lisa LaMotta • Sept. 14, 2017

Bristol, Roche tap Halozyme for tech platform

Between upfront, milestone and royalty payments, the separate licensing agreements could be worth more than $2 billion combined.

By Jacob Bell • Sept. 14, 2017

Onxeo finds a partner to progress its cancer medication

A licensing deal with private drugmaker Monopar should help the Paris-based company push Validive into late-stage testing.

By Jacob Bell • Sept. 13, 2017

Sobi looking to make a deal, report says

The Swedish rare disease drugmaker could be looking to boost revenues through M&A, according to an analyst.

By Lisa LaMotta • Sept. 12, 2017